Depomed To Present At UBS Global Healthcare Conference
NEWARK, Calif., May 16, 2013
NEWARK, Calif., May 16, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today
announced that it will be presenting at the UBS Global Healthcare Conference
at the Sheraton New York Hotel in New York City.
The presentation at the UBS conference is scheduled for 10 am EDT (7 am PDT)
on Tuesday, May 21, 2013. The presentation will be webcast, and the webcast
can be accessed via the Investor Relations page of the Depomed website at
www.depomed.com. A recording of the webcast will be archived for 30 days on
the company's website.
Depomed, Inc.is a specialty pharmaceutical company with three approved and
marketed products. Gralise^®(gabapentin) is a once-daily treatment approved
for the management of postherpetic neuralgia (PHN). Zipsor^®(diclofenac
potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug
(NSAID) indicated for relief of mild to moderate acute pain in adults.
Glumetza^®(metformin hydrochloride extended release tablets) is approved for
use in adults with type 2 diabetes and is commercialized bySantarus,
Inc.inthe United States. The company formulates its products and product
candidates with its proven, proprietary Acuform^®drug delivery technology,
which is designed to improve existing oral medications, allowing for extended
release of medications to the upper gastrointestinal tract when dosed with
food. Additional information aboutDepomedmay be found on its
August J. Moretti
Depomed, Inc. 510.744.8000
SOURCE Depomed, Inc.
Press spacebar to pause and continue. Press esc to stop.